CN116018154A - 用于治疗假单胞菌属感染的噬菌体组合物 - Google Patents

用于治疗假单胞菌属感染的噬菌体组合物 Download PDF

Info

Publication number
CN116018154A
CN116018154A CN202180037127.9A CN202180037127A CN116018154A CN 116018154 A CN116018154 A CN 116018154A CN 202180037127 A CN202180037127 A CN 202180037127A CN 116018154 A CN116018154 A CN 116018154A
Authority
CN
China
Prior art keywords
seq
phage
polynucleotide sequence
identity
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180037127.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN116018154A9 (zh
Inventor
S·莱米雷
S·L·科拉
B·C·瓦纳姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amata Pharmaceutical
Original Assignee
Amata Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amata Pharmaceutical filed Critical Amata Pharmaceutical
Publication of CN116018154A publication Critical patent/CN116018154A/zh
Publication of CN116018154A9 publication Critical patent/CN116018154A9/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10111—Myoviridae
    • C12N2795/10171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10221—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10232—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/10011—Details dsDNA Bacteriophages
    • C12N2795/10211—Podoviridae
    • C12N2795/10271—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180037127.9A 2020-04-27 2021-04-27 用于治疗假单胞菌属感染的噬菌体组合物 Pending CN116018154A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063016132P 2020-04-27 2020-04-27
US63/016,132 2020-04-27
PCT/US2021/029412 WO2021222257A1 (en) 2020-04-27 2021-04-27 Bacteriophage compositions for treating pseudomonas infection

Publications (2)

Publication Number Publication Date
CN116018154A true CN116018154A (zh) 2023-04-25
CN116018154A9 CN116018154A9 (zh) 2023-10-24

Family

ID=76284135

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180037127.9A Pending CN116018154A (zh) 2020-04-27 2021-04-27 用于治疗假单胞菌属感染的噬菌体组合物

Country Status (8)

Country Link
US (3) US12594312B2 (enExample)
EP (1) EP4142760A1 (enExample)
JP (1) JP2023523319A (enExample)
CN (1) CN116018154A (enExample)
AU (1) AU2021263735A1 (enExample)
CA (1) CA3179361A1 (enExample)
IL (1) IL296741A (enExample)
WO (1) WO2021222257A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1879573T3 (pl) 2005-05-10 2013-05-31 Incyte Holdings Corp Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania
US12594312B2 (en) * 2020-04-27 2026-04-07 Armata Pharmaceuticals, Inc. Bacteriophage compositions for treating Pseudomonas infection
WO2025143108A1 (ja) * 2023-12-27 2025-07-03 株式会社Arrowsmith 緑膿菌バクテリオファージ
WO2025219447A1 (en) 2024-04-17 2025-10-23 Hun-Ren Biological Research Centre Szeged Region-specific phage compositions

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104519893A (zh) * 2012-03-19 2015-04-15 药物技术业制药技术股份有限公司 用于治疗细菌感染的包含抗细菌噬菌体的混合物的组合物及其使用方法
EP2865383A1 (en) * 2013-10-25 2015-04-29 Pherecydes Pharma Phage therapy of pseudomonas infections
EP3018201A1 (en) * 2014-11-07 2016-05-11 Pherecydes Pharma Phage therapy
WO2019136108A1 (en) * 2018-01-02 2019-07-11 Ampliphi Biosciences Corporation Bacteriophage compositions for treating pseudomonas infections
CN110612349A (zh) * 2017-02-17 2019-12-24 尹特荣生物科技株式会社 新型铜绿假单胞菌噬菌体Pse-AEP-3及其用于抑制铜绿假单胞菌的增殖的用途
CN110691603A (zh) * 2016-12-05 2020-01-14 抗菌技术生物技术研究与发展股份有限公司 包含呼吸道抗菌噬菌体的噬菌体组合物及其使用方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12594312B2 (en) 2020-04-27 2026-04-07 Armata Pharmaceuticals, Inc. Bacteriophage compositions for treating Pseudomonas infection

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104519893A (zh) * 2012-03-19 2015-04-15 药物技术业制药技术股份有限公司 用于治疗细菌感染的包含抗细菌噬菌体的混合物的组合物及其使用方法
EP2865383A1 (en) * 2013-10-25 2015-04-29 Pherecydes Pharma Phage therapy of pseudomonas infections
EP3018201A1 (en) * 2014-11-07 2016-05-11 Pherecydes Pharma Phage therapy
CN110691603A (zh) * 2016-12-05 2020-01-14 抗菌技术生物技术研究与发展股份有限公司 包含呼吸道抗菌噬菌体的噬菌体组合物及其使用方法
CN110612349A (zh) * 2017-02-17 2019-12-24 尹特荣生物科技株式会社 新型铜绿假单胞菌噬菌体Pse-AEP-3及其用于抑制铜绿假单胞菌的增殖的用途
WO2019136108A1 (en) * 2018-01-02 2019-07-11 Ampliphi Biosciences Corporation Bacteriophage compositions for treating pseudomonas infections

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PIETER-JAN CEYSSENS ET AL.,: ""Comparative analysis of the widespread and conserved PB1-like viruses infecting Pseudomonas aeruginosa"", 《ENVIRONMENTAL MICROBIOLOGY》, vol. 11, no. 11, 31 December 2009 (2009-12-31), pages 2875 - 2880 *
李亚辉等: ""铜绿假单胞菌宽谱噬菌体PL39生物学特性研究"", 《中国病原生物学杂志》, vol. 11, no. 2, 28 February 2016 (2016-02-28), pages 144 - 147 *

Also Published As

Publication number Publication date
US20230174954A1 (en) 2023-06-08
IL296741A (en) 2022-11-01
CN116018154A9 (zh) 2023-10-24
US20240226205A1 (en) 2024-07-11
AU2021263735A1 (en) 2022-10-27
WO2021222257A1 (en) 2021-11-04
US12594312B2 (en) 2026-04-07
JP2023523319A (ja) 2023-06-02
US20210330722A1 (en) 2021-10-28
CA3179361A1 (en) 2021-11-04
EP4142760A1 (en) 2023-03-08

Similar Documents

Publication Publication Date Title
CN116018154A (zh) 用于治疗假单胞菌属感染的噬菌体组合物
US12239677B2 (en) Therapeutic bacteriophage compositions for treating Staphylococcus infection
JP7449967B2 (ja) 療法バクテリオファージ組成物
US20250170195A1 (en) Bacteriophage compositions for treating pseudomonas infections
US20210187046A1 (en) Cocktail compositions comprising respiratory antibacterial phages and methods of use thereof
Rahimi et al. Characterization of novel bacteriophage PSKP16 and its therapeutic potential against β-lactamase and biofilm producer strain of K2-Hypervirulent Klebsiella pneumoniae pneumonia infection in mice model
HK40092898A (zh) 用於治疗假单胞菌属感染的噬菌体组合物
CA3157249C (en) Cocktail compositions comprising respiratory antibacterial phages and methods of use thereof
AU2019205241C1 (en) Bacteriophage compositions for treating Pseudomonas infections
HK40040296A (en) Therapeutics bacteriophage compositions for treating staphylococcus infection
JP2023513934A (ja) ブドウ球菌感染症を処置するためのバクテリオファージ組成物
JP2024530170A (ja) 改善された抗微生物活性を有するバクテリオファージ

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CI02 Correction of invention patent application
CI02 Correction of invention patent application

Correction item: Sequence table

Correct: have

Number: 17-01

Page: ??

Volume: 39

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40092898

Country of ref document: HK